Ale's World of Stocks on $FRNM (Nov 15, 2026)
FRNM is a neutral, not-yet-buy for the speaker. Its colon-cancer blood test is FDA-approved, its lung-cancer test has breakthrough designation and it has a rollout partner, but high sales growth has not reduced losses, which stay flat or worsen; U.S. colon-test sales sit with a partner that also owns a competing test, a conflict to monitor, and barriers to entry are low. He sees long-term potential but ranks FRNM slightly below a higher-growth peer (he would pick the peer from $1,000 of either despite FRNM's higher minimum price) and will not buy soon, needing several years of performance.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
in the second deal, we have a brand new public company , probably unheard of by most ordinary investors, at least not yet. It is Freenome, a company specializing in cancer detection using artificial intelligence, and its code is FRNM.
Google currently owns about $30 million of its own shares after going public last July through a merger with a special purpose acquisition company (SPAC). Upon reviewing the stock chart, we find that it has experienced sharp fluctuations.
After a recent crash, its price has now stabilized at a level slightly below its initial public offering (IPO) levels .
But what makes this company interesting is that Freenome uses artificial intelligence to detect cancer early through a simple routine blood test. For example, consider how a colorectal cancer screening test works.
There are currently approximately 50 to 60 million eligible Americans over the age of 45 who completely avoid getting tested, mainly because traditional colonoscopies are difficult to perform, require a lot of preparation, and even take a whole day off work, and stool tests are not a pleasant experience either.
Freenome’s pioneering Simple Screen CRC test offers a solution to this problem, allowing doctors to screen for colon cancer during routine annual checkups using only a small blood sample .
The test had already received approval from the US Food and Drug Administration last July, and was officially launched at the end of September. Even better, instead of trying to build a huge sales team from scratch, Freenome partnered with healthcare giant Exact Laboratories to manage the test rollout in the United States, which already has 800 trained delegates in more than 2,000 clinical sites ordering test kits.
Through this deal, Freenome has already raised more than $240 million as an upfront payment, and can also earn up to $885 million in total profits when certain milestones are reached, plus 10% as revenue on every test sold.
In addition, it's not just colon cancer; their blood test for lung cancer received a " breakthrough discovery" designation from the U.S. Food and Drug Administration last August, giving them full rights to market this test, as well as their other suite of tests for multiple types of cancer.
However, there are still some real risks that make me, at least for the time being, remain neutral. Firstly, although sales are indeed growing at high rates, their losses remain the same or even worse in some years.
Second, Freenome handed over full control of the U.S. sales of the colon cancer test to Exact, which also owns Cologuard, the manufacturer that goes by the name Exact Sciences.
This creates a potential conflict of interest if Exact promotes its own test more aggressively than Freenome.
Therefore, this matter should be monitored. Finally, this is not an area that excites me much at the moment. I believe they have potential, but it's more of a long-term investment, and I don't see major barriers to market entry.
Therefore, I prefer to classify them perhaps slightly lower than obsidian, which I see as having higher growth potential overall.
It is true that Freedom has a higher minimum price, but if I were offered $1,000 of either stock, I would choose Obsidian for its higher long-term growth potential .
However, I do not intend to buy either of them anytime soon; I need to see how they perform for several more years before considering them a serious investment.